Literature DB >> 2016526

Immunologic and structural characterization of the dominant 66- to 73-kDa antigens of Borrelia burgdorferi.

B J Luft1, P D Gorevic, W Jiang, P Munoz, R J Dattwyler.   

Abstract

The 66- to 73-kDa proteins of Borrelia burgdorferi are dominant immunogens and expressed in all strains of B. burgdorferi. The humoral response to these Ag occurs relatively early during the course of infection. Two-dimensional Western blot analysis of this group of Ag revealed them to consist of a tetrad of proteins with apparent molecular mass of 66, 68, 71, and 73 kDa. Furthermore, in this study we demonstrate the 66-kDa protein to be a potent inducer of lymphoproliferation in the patient immune to B. burgdorferi. Monospecific polyclonal antibodies and mAb demonstrate that each of these proteins was immunologically distinct. However, direct amino acid sequence of the 66- and 68-kDa Ag was almost identical and had a high level of sequence similarity to the GroEL heat-shock protein (Hsp60) of Escherichia coli and the 60-kDa immunodominant protein of Treponema pallidum. The amino terminal sequence of the 71- and 73-kDa proteins of B. burgdorferi was almost identical and these proteins had remarkable sequence similarity to the DnaK heat-shock protein of E. coli (Hsp70). It appears likely, therefore, that proteins related to the heat-shock family are potent immunogens of B. burgdorferi.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2016526

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Validity of interpretation criteria for standardized Western blots (immunoblots) for serodiagnosis of Lyme borreliosis based on sera collected throughout Europe.

Authors:  U Hauser; G Lehnert; B Wilske
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of Borrelia burgdorferi and diagnosis of Lyme disease.

Authors:  Thomas B Ledue; Marilyn F Collins; John Young; Martin E Schriefer
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

3.  A survey of Q-fever in Sweden.

Authors:  A Macellaro; A Akesson; L Norlander
Journal:  Eur J Epidemiol       Date:  1993-03       Impact factor: 8.082

4.  Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans.

Authors:  M E Aguero-Rosenfeld; J Nowakowski; S Bittker; D Cooper; R B Nadelman; G P Wormser
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

5.  Glycosphingolipid-binding protein of Borrelia burgdorferi sensu lato.

Authors:  K Kaneda; T Masuzawa; K Yasugami; T Suzuki; Y Suzuki; Y Yanagihara
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Subcellular localization and chaperone activities of Borrelia burgdorferi Hsp60 and Hsp70.

Authors:  A Scopio; P Johnson; A Laquerre; D R Nelson
Journal:  J Bacteriol       Date:  1994-11       Impact factor: 3.490

7.  Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi.

Authors:  R A Kalish; J M Leong; A C Steere
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

8.  Evaluation of genetic divergence among Borrelia burgdorferi isolates by use of OspA, fla, HSP60, and HSP70 gene probes.

Authors:  R Wallich; C Helmes; U E Schaible; Y Lobet; S E Moter; M D Kramer; M M Simon
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

9.  An OspA antigen-capture enzyme-linked immunosorbent assay for detecting North American isolates of Borrelia burgdorferi in larval and nymphal Ixodes dammini.

Authors:  T R Burkot; R A Wirtz; B Luft; J Piesman
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

10.  Borrelia burgdorferi HSP70 homolog: characterization of an immunoreactive stress protein.

Authors:  J Anzola; B J Luft; G Gorgone; R J Dattwyler; C Soderberg; R Lahesmaa; G Peltz
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.